Lysosomal Storage Disorders Shed Light on Lysosomal Dysfunction in Parkinson’s Disease

The lysosome is a central player in the cell, acting as a clearing house for macromolecular degradation, but also plays a critical role in a variety of additional metabolic and regulatory processes. The lysosome has recently attracted the attention of neurobiologists and neurologists since a number of neurological diseases involve a lysosomal component. Among these is Parkinson’s disease (PD). While heterozygous and homozygous mutations in GBA1 are the highest genetic risk factor for PD, studies performed over the past decade have suggested that lysosomal loss of function is likely involved in PD pathology, since a significant percent of PD patients have a mutation in one or more genes that cause a lysosomal storage disease (LSD). Although the mechanistic connection between the lysosome and PD remains somewhat enigmatic, significant evidence is accumulating that lysosomal dysfunction plays a central role in PD pathophysiology. Thus, lysosomal dysfunction, resulting from mutations in lysosomal genes, may enhance the accumulation of α-synuclein in the brain, which may result in the earlier development of PD.

[1]  D. Priestman,et al.  Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease , 2019, Molecular Neurodegeneration.

[2]  D. Arkadir,et al.  Prodromal substantia nigra sonography undermines suggested association between substrate accumulation and the risk for GBA‐related Parkinson's disease , 2019, European journal of neurology.

[3]  N. Hattori,et al.  Altered regulation of serum lysosomal acid hydrolase activities in Parkinson's disease: A potential peripheral biomarker? , 2019, Parkinsonism & related disorders.

[4]  A. Brunetti,et al.  Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study. , 2018, Parkinsonism & related disorders.

[5]  Ottavio Arancio,et al.  Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations , 2018, Autophagy.

[6]  A. Mirelman,et al.  Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene. , 2018, Parkinsonism & related disorders.

[7]  Gennifer E. Merrihew,et al.  Glucocerebrosidase deficiency promotes protein aggregation through dysregulation of extracellular vesicles , 2018, PLoS genetics.

[8]  Lauren C. Boudewyn,et al.  Current concepts in the neuropathogenesis of mucolipidosis type IV , 2018, Journal of neurochemistry.

[9]  Joseph R. Mazzulli,et al.  Is Parkinson's disease a lysosomal disorder? , 2018, Brain : a journal of neurology.

[10]  R. Postuma,et al.  The GBA p.Trp378Gly mutation is a probable French‐Canadian founder mutation causing Gaucher disease and synucleinopathies , 2018, Clinical genetics.

[11]  R. Barker,et al.  The motor and cognitive features of Parkinson’s disease in patients with concurrent Gaucher disease over 2 years: a case series , 2018, Journal of Neurology.

[12]  Gregory A. Wyant,et al.  NUFIP1 is a ribosome receptor for starvation-induced ribophagy , 2018, Science.

[13]  K. Ozono,et al.  Unfolded protein response is activated in Krabbe disease in a manner dependent on the mutation type , 2018, Journal of Human Genetics.

[14]  W. Chung,et al.  Alpha galactosidase A activity in Parkinson's disease , 2018, Neurobiology of Disease.

[15]  D. Priestman,et al.  Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain , 2018, Neurobiology of Aging.

[16]  A. Schapira,et al.  Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications , 2018, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[17]  Jianhua Zhang,et al.  The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein , 2018, Neurobiology of Disease.

[18]  S. Jeon,et al.  Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide , 2018, Neuron.

[19]  K. Sango,et al.  Pathological role of lipid interaction with α-synuclein in Parkinson's disease , 2018, Neurochemistry International.

[20]  M. Duchen,et al.  Crosstalk between Lysosomes and Mitochondria in Parkinson's Disease , 2017, Front. Cell Dev. Biol..

[21]  E. Ginns,et al.  Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course. , 2017, Molecular genetics and metabolism.

[22]  Andrew R. Bassett,et al.  Alpha-synuclein induces the unfolded protein response in Parkinson’s disease SNCA triplication iPSC-derived neurons , 2017, Human molecular genetics.

[23]  R. Desnick,et al.  Parkinson's disease prevalence in Fabry disease: A survey study , 2017, Molecular genetics and metabolism reports.

[24]  S. Chandra,et al.  Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease , 2017, The Journal of Neuroscience.

[25]  M. Nalls,et al.  A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci , 2017, Nature Genetics.

[26]  D. Dickson,et al.  Impaired endo-lysosomal membrane integrity accelerates the seeding progression of α-synuclein aggregates , 2017, Scientific Reports.

[27]  S. Mole,et al.  NCLs and ER: A stressful relationship , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[28]  Simon C. Potter,et al.  Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease , 2017, Brain : a journal of neurology.

[29]  M. Duchen,et al.  Mitochondrial Dysfunction and Neurodegeneration in Lysosomal Storage Disorders. , 2017, Trends in molecular medicine.

[30]  A. Sidhu,et al.  ER stress and Parkinson's disease: Pathological inputs that converge into the secretory pathway , 2016, Brain Research.

[31]  W. Dauer,et al.  Endolysosomal dysfunction in Parkinson's disease: Recent developments and future challenges , 2016, Movement disorders : official journal of the Movement Disorder Society.

[32]  J. Hardy,et al.  Perspective: Finding common ground , 2016, Nature.

[33]  R. Barker,et al.  Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's , 2016, Annals of neurology.

[34]  C. Mariani,et al.  Survival and dementia in GBA‐associated Parkinson's disease: The mutation matters , 2016, Annals of neurology.

[35]  D. Krainc,et al.  Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons , 2016, The Journal of Neuroscience.

[36]  E. Schuchman,et al.  Types A and B Niemann-Pick Disease. , 2016, Pediatric endocrinology reviews : PER.

[37]  Yonatan Stelzer,et al.  Parkinson-associated risk variant in enhancer element produces subtle effect on target gene expression , 2016, Nature.

[38]  A. Schapira,et al.  The relationship between glucocerebrosidase mutations and Parkinson disease , 2016, Journal of neurochemistry.

[39]  I. Vattulainen,et al.  Selective effect of cell membrane on synaptic neurotransmission , 2016, Scientific Reports.

[40]  A. Schapira,et al.  Endoplasmic reticulum and lysosomal Ca2+ stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts , 2016, Cell calcium.

[41]  Nir Giladi,et al.  The emerging role of SMPD1 mutations in Parkinson's disease: Implications for future studies. , 2015, Parkinsonism & related disorders.

[42]  R. Gershoni-baruch,et al.  The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. , 2015, Parkinsonism & related disorders.

[43]  Jing Yang,et al.  No association of FAM47E rs6812193, SCARB2 rs6825004 and STX1B rs4889603 polymorphisms with Parkinson’s disease in a Chinese Han population , 2015, Journal of Neural Transmission.

[44]  G. Rouleau,et al.  Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease , 2015, Autophagy.

[45]  B. H. Wang,et al.  No evidence for substrate accumulation in Parkinson brains with GBA mutations , 2015, Movement disorders : official journal of the Movement Disorder Society.

[46]  K. Marder,et al.  Gene-Wise Association of Variants in Four Lysosomal Storage Disorder Genes in Neuropathologically Confirmed Lewy Body Disease , 2015, PloS one.

[47]  P. Calabresi,et al.  Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies , 2015, Molecular Neurodegeneration.

[48]  K. Marder,et al.  Differential effects of severe vs mild GBA mutations on Parkinson disease , 2015, Neurology.

[49]  O. Isacson,et al.  Progressive decline of glucocerebrosidase in aging and Parkinson's disease , 2015, Annals of Clinical and Translational Neurology.

[50]  D. Krainc,et al.  LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance , 2014, Proceedings of the National Academy of Sciences.

[51]  G. Rizzo,et al.  Arylsulphatase A activity in familial parkinsonism: a pathogenetic role? , 2014, Journal of Neurology.

[52]  S. Gygi,et al.  iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis , 2014, Nature Communications.

[53]  W. Chung,et al.  Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. , 2014, JAMA neurology.

[54]  C. Hetz,et al.  Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1 , 2014, Proceedings of the National Academy of Sciences.

[55]  M. Duchen,et al.  Quality control gone wrong: mitochondria, lysosomal storage disorders and neurodegeneration , 2014, British journal of pharmacology.

[56]  G. Halliday,et al.  Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. , 2014, Brain : a journal of neurology.

[57]  J. Nutt,et al.  Parkinsonism syndrome in heterozygotes for Niemann–Pick C1 , 2013, Journal of the Neurological Sciences.

[58]  H. Steller,et al.  Unfolded protein response in Gaucher disease: from human to Drosophila , 2013, Orphanet Journal of Rare Diseases.

[59]  S. Cherqui,et al.  Upregulation of the Rab27a-Dependent Trafficking and Secretory Mechanisms Improves Lysosomal Transport, Alleviates Endoplasmic Reticulum Stress, and Reduces Lysosome Overload in Cystinosis , 2013, Molecular and Cellular Biology.

[60]  A. Mirelman,et al.  The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease , 2013, Neurology.

[61]  Andrea Ballabio,et al.  Signals from the lysosome: a control centre for cellular clearance and energy metabolism , 2013, Nature Reviews Molecular Cell Biology.

[62]  Pierre Germain,et al.  hLGDB: a database of human lysosomal genes and their regulation , 2013, Database J. Biol. Databases Curation.

[63]  D. Brooks,et al.  Exocytosis is impaired in mucopolysaccharidosis IIIA mouse chromaffin cells , 2012, Neuroscience.

[64]  Shivananda,et al.  Niemann-pick disease type a presenting as unilateral tremors , 2012, Indian Pediatrics.

[65]  A. Bunker,et al.  Strong preferences of dopamine and l‐dopa towards lipid head group: importance of lipid composition and implication for neurotransmitter metabolism , 2012, Journal of neurochemistry.

[66]  A. Ballabio,et al.  Autophagy in lysosomal storage disorders , 2012, Autophagy.

[67]  D. Vassilatis,et al.  Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[68]  A. Futerman,et al.  Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond , 2011, Movement disorders : official journal of the Movement Disorder Society.

[69]  R. Sidman,et al.  CNS expression of glucocerebrosidase corrects α-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy , 2011, Proceedings of the National Academy of Sciences.

[70]  Nicholas Eriksson,et al.  Web-Based Genome-Wide Association Study Identifies Two Novel Loci and a Substantial Genetic Component for Parkinson's Disease , 2011, PLoS genetics.

[71]  M. Vila,et al.  Pathogenic Lysosomal Depletion in Parkinson's Disease , 2010, The Journal of Neuroscience.

[72]  F. Platt,et al.  Common and Uncommon Pathogenic Cascades in Lysosomal Storage Diseases* , 2010, The Journal of Biological Chemistry.

[73]  F. Platt,et al.  Lipids on Trial: The Search for the Offending Metabolite in Niemann‐Pick type C Disease , 2010, Traffic.

[74]  M. Nalls,et al.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. , 2009, The New England journal of medicine.

[75]  P. Saftig,et al.  Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function , 2009, Nature Reviews Molecular Cell Biology.

[76]  C. Warren Olanow,et al.  Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions , 2009, Neurobiology of Disease.

[77]  K. Doheny,et al.  Genomewide association study for susceptibility genes contributing to familial Parkinson disease , 2009, Human Genetics.

[78]  P. Calabresi,et al.  Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[79]  W. Scheper,et al.  Activation of the unfolded protein response in Parkinson's disease. , 2007, Biochemical and biophysical research communications.

[80]  Atul Mehta,et al.  Lysosomal Storage Disorders , 2005 .

[81]  D. Steindler,et al.  GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. , 2004, Molecular cell.

[82]  S. Walkley Secondary accumulation of gangliosides in lysosomal storage disorders. , 2004, Seminars in cell & developmental biology.

[83]  Anthony H. Futerman,et al.  The cell biology of lysosomal storage disorders , 2004, Nature Reviews Molecular Cell Biology.

[84]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[85]  P. Meikle,et al.  Diagnosis of lysosomal storage disorders: evaluation of lysosome-associated membrane protein LAMP-1 as a diagnostic marker. , 1997, Clinical chemistry.

[86]  A. Mubaidin,et al.  Pallido‐pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor‐Rakeb syndrome , 1994, Acta neurologica Scandinavica.

[87]  Jan Grøndahl Tapeto‐retinal degeneration in four Norwegian counties I , 1986, Clinical genetics.

[88]  C. Duve,et al.  Exploring cells with a centrifuge. , 1975, Science.

[89]  Changhe Shi,et al.  SMPD1 variants in Chinese Han patients with sporadic Parkinson's disease. , 2017, Parkinsonism & related disorders.

[90]  C. Galvagnion The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson's Disease. , 2017, Journal of Parkinson's disease.

[91]  H. Braak,et al.  100 years of Lewy pathology , 2013, Nature Reviews Neurology.

[92]  C. de Duve The lysosome turns fifty , 2005, Nature cell biology.

[93]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.